Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DG49 | ISIN: US4834971032 | Ticker-Symbol: 4XC1
Tradegate
04.09.25 | 20:14
13,100 Euro
+0,77 % +0,100
1-Jahres-Chart
KALVISTA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
KALVISTA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
12,80013,20009:45
12,80013,20007:30

Aktuelle News zur KALVISTA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025194KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September 11, 2025 to provide an operational update and release...
► Artikel lesen
DoKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)324KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted two newly-hired employees inducement options to purchase an...
► Artikel lesen
27.08.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025221KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025...
► Artikel lesen
21.08.KalVista Pharmaceuticals terminiert jährliche Hauptversammlung für Juni 20265
21.08.KalVista Pharmaceuticals, Inc. - 8-K, Current Report1
25.07.KalVista, Biogen, Ionis get EU positive opinions for key drugs16
25.07.KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat4
KALVISTA PHARMACEUTICALS Aktie jetzt für 0€ handeln
25.07.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks524If approved, sebetralstat will be the first and only oral on-demand treatment for HAE in the European Union (EU) European Commission decision expected by early October 2025 KalVista Pharmaceuticals...
► Artikel lesen
17.07.MHRA approves KalVista Pharmaceuticals' Ekterly to treat hereditary angioedema attacks2
17.07.Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP15
17.07.JMP bestätigt "Market Outperform" für Kalvista und sieht erhebliches Potenzial für HAE-Medikament5
16.07.Kalvista: JMP bestätigt "Market Outperform" nach Zulassung von HAE-Medikament in Großbritannien4
16.07.JMP reiterates Market Outperform rating on Kalvista stock after UK approval1
16.07.KalVista Secures UK Approval For EKTERLY, First Oral On-Demand Treatment For Hereditary Angioedema1
15.07.KalVista gets UK nod for Ekterly1
15.07.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema378EKTERLY to be added to the Orphan Register and awarded 10 years of market exclusivity KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products...
► Artikel lesen
10.07.KalVista Pharmaceuticals, Inc. - 10-K, Annual Report4
10.07.Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins4
10.07.KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?3
10.07.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results1.175- Received FDA approval of EKTERLY® (sebetralstat)-the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway - - Six additional global regulatory submissions...
► Artikel lesen
Weiter >>
116 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1